Format

Send to

Choose Destination
Arch Cardiovasc Dis. 2013 Oct;106(10):511-6. doi: 10.1016/j.acvd.2013.06.053. Epub 2013 Sep 27.

Evaluation of the impact of the recent controversy over statins in France: the EVANS study.

Author information

1
Division of Coronary Artery Disease and Intensive Cardiac Care, Georges-Pompidou European Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Paris-Descartes, 20, rue Leblanc, 75015 Paris, France.

Abstract

BACKGROUND:

The effect of statins on the prevention of cardiovascular events is well-established. However, a recent controversy in France questioned the value of statins, especially in primary prevention.

AIMS:

To evaluate the impact of this controversy on patient adherence to statin therapy and its potential clinical impact.

METHODS:

All patients on statins were recruited consecutively from consultations over a period of 1 month (from March 2013) by five physicians in three centres. Patient demographics and co-morbidities were collected and adherence to statin therapy was evaluated with a questionnaire. We estimated the number of deaths and major cardiovascular events that could be induced per year.

RESULTS:

A total of 142 patients were included: 37 in primary prevention (mean age, 68.0±13.1 years; 41% women); 105 in secondary prevention (mean age, 67.6±12.1 years; 20% women). In primary prevention, 24.3% of patients intended to stop statins versus 8.6% in secondary prevention (P<0.001). In France, if the percentages of medication discontinuations following the controversy were actually similar to those we found in our survey, 4992 major cardiovascular events, including 1159 deaths, would be induced in 1 year.

CONCLUSION:

Recent controversy over statins could induce a large proportion of patients to stop their medication and generate a large number of major cardiovascular events.

KEYWORDS:

Adherence; Adhérence; BMI; Body Mass Index; CABG; Coronary Artery Bypass Graft; Cost-effectiveness; Coût efficacité; LDL; Low-Density Lipoprotein; MI; Myocardial Infarction; PCI; Percutaneous Coronary Intervention; Prevention; Prévention; Statines; Statins

PMID:
24080324
DOI:
10.1016/j.acvd.2013.06.053
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center